SOURCE: Barrier Therapeutics, Inc.

October 24, 2006 16:00 ET

Barrier Therapeutics to Release Third Quarter 2006 Financial Results on October 31, 2006

Company to Host Conference Call at 4:30 p.m. ET on October 31, 2006

PRINCETON, NJ -- (MARKET WIRE) -- October 24, 2006 -- Barrier Therapeutics, Inc. (NASDAQ: BTRX), a pharmaceutical company developing and commercializing products in the field of dermatology, is scheduled to release financial results for the third quarter of 2006 on Tuesday, October 31, 2006 at approximately 3:30 p.m. Eastern Time. The Company will sponsor a conference call on October 31st at 4:30 p.m. Eastern Time to provide a company update and discuss the financial results for the quarter. Interested investors can listen to the call live over the Internet on the investor relations section of the Company's web site located at http://www.barriertherapeutics.com or by dialing 1-888-868-9083 (U.S.) or 1-973-935-8512 (International) and using conference ID code: 8035730.

What:      Barrier Therapeutics, Inc. Third Quarter 2006 Corporate Update
           and  Financial Results Conference Call

When:      Tuesday, October 31st at 4:30 p.m. Eastern Time

Where:     The investor relations section of the Company's web site located
           at http://www.barriertherapeutics.com

How:       Live over the Internet -- Simply log on to the web at the
           address above, or dial 1-888-868-9083 (U.S.) or 1-973-935-8512
           (International) and use conference ID code: 8035730
Barrier Therapeutics, Inc. is a pharmaceutical company focused on the discovery, development and commercialization of pharmaceutical products in the field of dermatology. Barrier Therapeutics currently markets three pharmaceutical products in the United States: Xolegel™ (ketoconazole, USP) Gel, 2%, Vusion™ (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment and Solagé® (mequinol 2.0%, tretinoin 0.01%) Topical Solution. Barrier has other product candidates in various stages of clinical development for the treatment of onychomycosis, psoriasis, acne, and fungal infections. The Company is headquartered in Princeton, New Jersey and has wholly owned subsidiaries in Geel, Belgium and Ontario, Canada.

Contact Information

  • Contact:
    Barrier Therapeutics, Inc.
    Anne M. VanLent
    609-945-1202

    Noonan Russo
    Matt Haines
    212-845-4235